Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
Summary
This study will recruit schizophrenia patients who use cannabis recreationally. Each participant will attend the laboratory on three occasions: an initial visit to check that they are safe to join the study and two days of testing. Participants will be administered, in a randomized order, a pre-treatment with either CBD (1000mg) orally or a matching placebo. On both experiments, participants will then inhale cannabis containing THC. The THC administration will follow a standardised inhalation procedure using a medical-grade vaporizer device. Participants will complete a series of tasks measuring cognition, psychosis, anxiety and other subjective experiences. The study will be carried out at the NIHR-Wellcome Trust Clinical Research Facility at King's College Hospital.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-07-07
- Completion
- 2023-07-07
Outcome
Missed primary endpoint
paper Delayed verbal recall after cannabis administration was 3.5 words (95% confidence interval [CI]: 2.5-4.5) following pre-treatment with CBD, compared to 4.8 words PMID 40702165 ↗
paper mean difference [MD] = -1.3 [95% CI: -2.0 to -0.6]; p = 0.001 PMID 40702165 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 1000 mg | Oral |
| Subject | Dronabinol | Other / unclassified | 20 mg | Inhaled |
| Subject | Dronabinol | Other / unclassified | 60 mg | Inhaled |